Dermata Therapeutics Inc. Common Stock is a biotechnology business based in the US. Dermata Therapeutics IncCommon Stock shares (DRMA) are listed on the NASDAQ and all prices are listed in US Dollars. Dermata Therapeutics IncCommon Stock employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $1.72 |
|---|---|
| 52-week range | $1.41 - $50.00 |
| 50-day moving average | $2.65 |
| 200-day moving average | $3.84 |
| Wall St. target price | $11.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.09 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.72 from 2022-01-20
| 1 week (2022-01-14) | 10.97% |
|---|---|
| 1 month (2021-12-21) | -21.10% |
| 3 months (2021-10-21) | -61.43% |
| 6 months (2021-07-21) | -96.56% |
| 1 year (2021-01-21) | -96.56% |
|---|---|
| 2 years (2020-01-21) | -96.56% |
| 3 years (2019-01-18) | 50 |
| 5 years (2017-01-20) | 50 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $1.50 |
| Market capitalisation | $14 million |
TTM: trailing 12 months
We're not expecting Dermata Therapeutics IncCommon Stock to pay a dividend over the next 12 months.
You may also wish to consider:
Dermata Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.